{"transactions":[{"id":698921,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date"}],"balance_after":44477,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":698920,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date"}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":698919,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-07-30","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date"}],"balance_after":44477,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":698918,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":44477,"derivative":{"exercise_price":8.15,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":698917,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":8.15,"expiration_date":"2036-07-07","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":698916,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":51890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":51890,"derivative":{"exercise_price":9.5,"expiration_date":"2034-12-12","underlying":"Common Stock","underlying_shares":51890},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":698915,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:07.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":9.5,"expiration_date":"2034-12-12","underlying":"Class A Common Stock","underlying_shares":51890},"source":{"system":"sec-edgar","filing":"0001193125-26-330504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330504/ownership.xml","form_type":"4"}},{"id":729105,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T20:29:05.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":13313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":13313,"derivative":{"exercise_price":15.23,"expiration_date":"2036-06-22","underlying":"Common Stock","underlying_shares":13313},"source":{"system":"sec-edgar","filing":"0001659085-26-000003","document":"wk-form4_1782246543.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000165908526000003/wk-form4_1782246543.xml","form_type":"4"}},{"id":729104,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T20:29:05.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":8141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,141 unvested RSUs."}],"balance_after":25388,"source":{"system":"sec-edgar","filing":"0001659085-26-000003","document":"wk-form4_1782246543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000165908526000003/wk-form4_1782246543.xml","form_type":"4"}},{"id":774296,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-05-18T20:15:54.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":21872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":21872,"derivative":{"exercise_price":30.76,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":21872},"source":{"system":"sec-edgar","filing":"0001659085-26-000002","document":"form4-05182026_080548.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000165908526000002/form4-05182026_080548.xml","form_type":"4"}},{"id":989866,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-24T21:08:30.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."},{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."}],"balance_after":13500,"derivative":{"exercise_price":1,"expiration_date":"2035-11-19","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001104659-25-115410","document":"tm2532045-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465925115410/tm2532045-4_4seq1.xml","form_type":"4"}},{"id":1104976,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T20:36:31.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":9341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 18, 2025 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":9341,"derivative":{"exercise_price":21.05,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":9341},"source":{"system":"sec-edgar","filing":"0001490978-25-000091","document":"wk-form4_1750451757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000091/wk-form4_1750451757.xml","form_type":"4"}},{"id":1104975,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:36:31.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":5997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2025 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,997 unvested RSUs."}],"balance_after":17247,"source":{"system":"sec-edgar","filing":"0001490978-25-000091","document":"wk-form4_1750451757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000091/wk-form4_1750451757.xml","form_type":"4"}},{"id":1144730,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-05-16T20:01:22.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":14522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in full on the earlier to occur of (i) May 15, 2026 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":14522,"derivative":{"exercise_price":34.23,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":14522},"source":{"system":"sec-edgar","filing":"0001415889-25-013397","document":"form4-05162025_080517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000141588925013397/form4-05162025_080517.xml","form_type":"4"}},{"id":1304245,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-13T21:30:14.000Z","date":"2025-01-10","kind":"purchase","planned":false,"acquired":true,"shares":9191,"price":2.72,"value":24999.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025."}],"balance_after":9191,"source":{"system":"sec-edgar","filing":"0001104659-25-003058","document":"tm253156-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465925003058/tm253156-1_4seq1.xml","form_type":"4"}},{"id":1352562,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-11-25T21:34:15.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":18900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."},{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."}],"balance_after":18900,"derivative":{"exercise_price":2.45,"expiration_date":"2034-11-20","underlying":"Common Stock","underlying_shares":18900},"source":{"system":"sec-edgar","filing":"0001104659-24-122595","document":"tm2429436-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465924122595/tm2429436-6_4seq1.xml","form_type":"4"}},{"id":1473131,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T20:19:13.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":8550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 18, 2024. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":8550,"derivative":{"exercise_price":19.32,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":8550},"source":{"system":"sec-edgar","filing":"0001490978-24-000057","document":"wk-form4_1718914747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000057/wk-form4_1718914747.xml","form_type":"4"}},{"id":1473130,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T20:19:13.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2024 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,000 unvested RSUs."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001490978-24-000057","document":"wk-form4_1718914747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000057/wk-form4_1718914747.xml","form_type":"4"}},{"id":1496293,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-05-31T12:58:04.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":11657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1. The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":11657,"derivative":{"exercise_price":29.33,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":11657},"source":{"system":"sec-edgar","filing":"0001415889-24-014970","document":"form4-05312024_120500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000141588924014970/form4-05312024_120500.xml","form_type":"4"}},{"id":1852143,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:56:00.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 15, 2023. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":12500,"derivative":{"exercise_price":45.26,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001490978-23-000076","document":"wk-form4_1686948952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000076/wk-form4_1686948952.xml","form_type":"4"}},{"id":1852142,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T20:56:00.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 15, 2023 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,250 unvested RSUs."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001490978-23-000076","document":"wk-form4_1686948952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000076/wk-form4_1686948952.xml","form_type":"4"}},{"id":1875871,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-05-26T20:35:21.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":9613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in full on the earlier to occur of (i) May 25, 2024 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":48255,"derivative":{"exercise_price":35.99,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":9613},"source":{"system":"sec-edgar","filing":"0001415889-23-008856","document":"form4-05262023_040502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000141588923008856/form4-05262023_040502.xml","form_type":"4"}},{"id":2229907,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:00:55.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":14907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 15, 2022. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":14907,"derivative":{"exercise_price":24.51,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":14907},"source":{"system":"sec-edgar","filing":"0001209191-22-037485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919122037485/doc4.xml","form_type":"4"}},{"id":2257732,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-05-24T20:18:20.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":8726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in full on the earlier to occur of (i) May 20, 2023 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":8726,"derivative":{"exercise_price":41.33,"expiration_date":"2032-05-20","underlying":"Common Stock","underlying_shares":8726},"source":{"system":"sec-edgar","filing":"0001104659-22-064252","document":"tm2216688-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000110465922064252/tm2216688-5_4seq1.xml","form_type":"4"}},{"id":2475330,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-13T23:58:42.000Z","date":"2021-12-09","kind":"grant","acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over 12 months."},{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over 12 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over 12 months."}],"balance_after":109000,"derivative":{"exercise_price":0.6938,"exercise_date":"2022-01-09","expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001104659-21-149222","document":"tm2135158-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465921149222/tm2135158-3_4seq1.xml","form_type":"4"}},{"id":2660925,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T21:01:00.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":8736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 17, 2021. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":8736,"derivative":{"exercise_price":76.08,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":8736},"source":{"system":"sec-edgar","filing":"0001209191-21-042100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919121042100/doc4.xml","form_type":"4"}},{"id":2669621,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-06-14T20:30:27.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in full on the earlier to occur of (i) May 20, 2022 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":13333,"derivative":{"exercise_price":32.5,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0000899243-21-023567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000089924321023567/doc4.xml","form_type":"4"}},{"id":2796951,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-10T23:18:58.000Z","date":"2021-03-08","kind":"exercise","acquired":false,"shares":12890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on February 5, 2020 and is fully vested."}],"balance_after":19,"derivative":{"exercise_price":17,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":12890},"source":{"system":"sec-edgar","filing":"0001209191-21-019596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919121019596/doc4.xml","form_type":"4"}},{"id":2796950,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-10T23:18:58.000Z","date":"2021-03-08","kind":"exercise","acquired":false,"shares":15885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on August 1, 2019. The shares underlying the option vested with respect to 25% of the shares on July 22, 2020 and the remainder are scheduled to vest in equal monthly installments through July 22, 2023."}],"balance_after":24246,"derivative":{"exercise_price":5.31,"expiration_date":"2029-08-01","underlying":"Common Stock","underlying_shares":15885},"source":{"system":"sec-edgar","filing":"0001209191-21-019596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919121019596/doc4.xml","form_type":"4"}},{"id":2796949,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-10T23:18:58.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":28775,"price":66.5452,"value":1914838.13,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.50 to $66.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-019596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919121019596/doc4.xml","form_type":"4"}},{"id":2796948,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-10T23:18:58.000Z","date":"2021-03-08","kind":"exercise","acquired":true,"shares":12890,"price":17,"value":219130.0,"ownership":{"direct":true},"balance_after":28775,"source":{"system":"sec-edgar","filing":"0001209191-21-019596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919121019596/doc4.xml","form_type":"4"}},{"id":2796947,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-10T23:18:58.000Z","date":"2021-03-08","kind":"exercise","acquired":true,"shares":15885,"price":5.31,"value":84349.35,"ownership":{"direct":true},"balance_after":15885,"source":{"system":"sec-edgar","filing":"0001209191-21-019596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000120919121019596/doc4.xml","form_type":"4"}},{"id":2818706,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T19:43:15.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":31,"price":2.39,"value":74.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":20472,"source":{"system":"sec-edgar","filing":"0001104659-21-030950","document":"tm218516-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465921030950/tm218516-5_4seq1.xml","form_type":"4"}},{"id":2884547,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-02-02T20:01:54.000Z","date":"2021-01-31","kind":"tax_withholding","acquired":false,"shares":37,"price":2.62,"value":96.94,"ownership":{"direct":true},"balance_after":20503,"source":{"system":"sec-edgar","filing":"0001104659-21-011108","document":"tm215099-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465921011108/tm215099-5_4seq1.xml","form_type":"4"}},{"id":2918646,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-01-05T17:16:03.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":32,"price":2.42,"value":77.44,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020."}],"balance_after":20540,"source":{"system":"sec-edgar","filing":"0001104659-21-001044","document":"tm211621-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465921001044/tm211621-5_4seq1.xml","form_type":"4"}},{"id":2962375,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-01T20:22:40.000Z","date":"2020-11-30","kind":"tax_withholding","acquired":false,"shares":312,"price":0.427,"value":133.224,"ownership":{"direct":true},"balance_after":205728,"source":{"system":"sec-edgar","filing":"0001104659-20-131223","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920131223/a4.xml","form_type":"4"}},{"id":2996215,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-11-02T19:07:45.000Z","date":"2020-10-31","kind":"tax_withholding","acquired":false,"shares":312,"price":0.4955,"value":154.596,"ownership":{"direct":true},"balance_after":206040,"source":{"system":"sec-edgar","filing":"0001104659-20-120642","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920120642/a4.xml","form_type":"4"}},{"id":3005088,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-10-16T10:08:24.000Z","date":"2020-10-14","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over 36 months."}],"balance_after":100000,"derivative":{"exercise_price":2.05,"exercise_date":"2020-11-14","expiration_date":"2030-10-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-20-115456","document":"tm2033244d4_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465920115456/tm2033244d4_form4.xml","form_type":"4"}},{"id":3018102,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-01T16:32:20.000Z","date":"2020-09-30","kind":"tax_withholding","acquired":false,"shares":312,"price":0.533,"value":166.296,"ownership":{"direct":true},"balance_after":206352,"source":{"system":"sec-edgar","filing":"0001104659-20-111080","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920111080/a4.xml","form_type":"4"}},{"id":3040623,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-02T17:16:27.000Z","date":"2020-08-31","kind":"tax_withholding","acquired":false,"shares":312,"price":0.6194,"value":193.2528,"ownership":{"direct":true},"balance_after":206664,"source":{"system":"sec-edgar","filing":"0001104659-20-101909","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920101909/a4.xml","form_type":"4"}},{"id":3049524,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2020-08-21T19:02:28.000Z","date":"2020-08-19","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 31, 2018, Nabriva Therapeutics plc (the \"Issuer\") granted the reporting person 22,500 restricted share units (\"RSUs\"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the \"Performance Condition\"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 31, 2018, Nabriva Therapeutics plc (the \"Issuer\") granted the reporting person 22,500 restricted share units (\"RSUs\"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the \"Performance Condition\"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001104659-20-097716","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920097716/a4.xml","form_type":"4"}},{"id":3049523,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-21T19:02:28.000Z","date":"2020-08-20","kind":"tax_withholding","acquired":false,"shares":3204,"price":0.6476,"value":2074.9104,"ownership":{"direct":true},"balance_after":206976,"source":{"system":"sec-edgar","filing":"0001104659-20-097716","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920097716/a4.xml","form_type":"4"}},{"id":3049522,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-21T19:02:28.000Z","date":"2020-08-19","kind":"exercise","acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units."}],"balance_after":210180,"source":{"system":"sec-edgar","filing":"0001104659-20-097716","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920097716/a4.xml","form_type":"4"}},{"id":3050644,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-08-20T23:59:34.000Z","date":"2020-08-18","kind":"grant","acquired":true,"shares":16583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in three equal annual installments beginning on August 21, 2021."}],"balance_after":16583,"derivative":{"exercise_price":24,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":16583},"source":{"system":"sec-edgar","filing":"0000899243-20-023121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000089924320023121/doc4.xml","form_type":"4"}},{"id":3068956,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-04T16:07:57.000Z","date":"2020-07-31","kind":"tax_withholding","acquired":false,"shares":312,"price":0.76,"value":237.12,"ownership":{"direct":true},"balance_after":198930,"source":{"system":"sec-edgar","filing":"0001104659-20-090278","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920090278/a4.xml","form_type":"4"}},{"id":3090641,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-02T16:06:15.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":312,"price":0.6746,"value":210.4752,"ownership":{"direct":true},"balance_after":199242,"source":{"system":"sec-edgar","filing":"0001104659-20-080539","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920080539/a4.xml","form_type":"4"}},{"id":3123092,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-06-03T06:08:05.000Z","date":"2020-05-31","kind":"tax_withholding","acquired":false,"shares":312,"price":1.14,"value":355.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total reported in Column 5 includes 6,187 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan (\"ESPP\") on May 29, 2020."}],"balance_after":199554,"source":{"system":"sec-edgar","filing":"0001104659-20-069188","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920069188/a4.xml","form_type":"4"}},{"id":3163304,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-05-04T18:32:38.000Z","date":"2020-04-30","kind":"tax_withholding","acquired":false,"shares":301,"price":0.5483,"value":165.0383,"ownership":{"direct":true},"balance_after":193679,"source":{"system":"sec-edgar","filing":"0001104659-20-056352","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920056352/a4.xml","form_type":"4"}},{"id":3185716,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-04-02T17:49:17.000Z","date":"2020-03-31","kind":"tax_withholding","acquired":false,"shares":301,"price":0.575,"value":173.075,"ownership":{"direct":true},"balance_after":193980,"source":{"system":"sec-edgar","filing":"0001104659-20-042582","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920042582/a4.xml","form_type":"4"}},{"id":3230572,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-03T21:32:02.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":301,"price":1.35,"value":406.35,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total reported in Column 5 includes 5,154 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan (\"ESPP\") on April 30, 2019 and 5,759 shares acquired under the ESPP on October 31, 2019."}],"balance_after":194281,"source":{"system":"sec-edgar","filing":"0001104659-20-028850","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920028850/a4.xml","form_type":"4"}},{"id":3282009,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-02-10T21:05:50.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":12909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest in full on February 5, 2021."}],"balance_after":12909,"derivative":{"exercise_price":17,"expiration_date":"2030-02-04","underlying":"Common Stock","underlying_shares":12909},"source":{"system":"sec-edgar","filing":"0000899243-20-003791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490978/000089924320003791/doc4.xml","form_type":"4"}},{"id":3281537,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2020-02-10T20:29:15.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":210000,"derivative":{"exercise_price":1.35,"expiration_date":"2030-02-05","underlying":"Ordinary Shares","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001104659-20-015174","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920015174/a4.xml","form_type":"4"}},{"id":3281536,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-10T20:29:15.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 105,000 restricted stock units. The total reported in Column 5 includes the 105,000 newly awarded restricted stock units."}],"balance_after":183669,"source":{"system":"sec-edgar","filing":"0001104659-20-015174","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920015174/a4.xml","form_type":"4"}},{"id":3290462,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-04T20:56:10.000Z","date":"2020-01-31","kind":"tax_withholding","acquired":false,"shares":4295,"price":1.35,"value":5798.25,"ownership":{"direct":true},"balance_after":78669,"source":{"system":"sec-edgar","filing":"0001104659-20-010900","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465920010900/a4.xml","form_type":"4"}},{"id":3428980,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-26T21:35:03.000Z","date":"2019-08-21","kind":"sale","acquired":false,"shares":3390,"price":2.08,"value":7051.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment is being filed solely to correct the transaction code from \"F\" to \"S\" for the sale of ordinary shares to satisfy tax withholding obligations in connection with the transaction reported in the Form 4 filed by the reporting person on August 21, 2019."}],"balance_after":19214,"source":{"system":"sec-edgar","filing":"0001104659-19-047348","document":"a4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465919047348/a4a.xml","form_type":"4/A","original_submission_date":"2019-08-21"}},{"id":3431726,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2019-08-21T21:22:34.000Z","date":"2019-08-19","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 31, 2018, Nabriva Therapeutics plc (the \"Issuer\") granted the reporting person 22,500 restricted share units (\"RSUs\"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the \"Performance Condition\"), and the remaining fifty percent (50%) of the RSUs will vest on the one (1) year anniversary of the Performance Condition."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 31, 2018, Nabriva Therapeutics plc (the \"Issuer\") granted the reporting person 22,500 restricted share units (\"RSUs\"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the \"Performance Condition\"), and the remaining fifty percent (50%) of the RSUs will vest on the one (1) year anniversary of the Performance Condition."}],"balance_after":11250,"derivative":{"underlying":"Ordinary Shares","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001104659-19-046858","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465919046858/a4.xml","form_type":"4"}},{"id":3431725,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-21T21:22:34.000Z","date":"2019-08-21","kind":"tax_withholding","acquired":false,"shares":3390,"price":2.08,"value":7051.2,"ownership":{"direct":true},"balance_after":19214,"source":{"system":"sec-edgar","filing":"0001104659-19-046858","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465919046858/a4.xml","form_type":"4"}},{"id":3431724,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-21T21:22:34.000Z","date":"2019-08-19","kind":"exercise","acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units."}],"balance_after":22604,"source":{"system":"sec-edgar","filing":"0001104659-19-046858","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465919046858/a4.xml","form_type":"4"}},{"id":3676614,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-04T16:07:29.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023.  Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":52500,"derivative":{"expiration_date":"2023-01-31","underlying":"Ordinary Shares","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001104659-19-005522","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465919005522/a4.xml","form_type":"4"}},{"id":3676613,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2019-02-04T16:07:29.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":138200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $1.90 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023.  Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":138200,"derivative":{"expiration_date":"2029-01-31","underlying":"Ordinary Shares","underlying_shares":138200},"source":{"system":"sec-edgar","filing":"0001104659-19-005522","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465919005522/a4.xml","form_type":"4"}},{"id":3919947,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2018-05-23T20:38:10.000Z","date":"2018-05-23","kind":"purchase","acquired":true,"shares":2000,"price":4.57,"value":9140.0,"ownership":{"direct":true},"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001104659-18-035539","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465918035539/a4.xml","form_type":"4"}},{"id":4078434,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-02T16:11:51.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration (\"FDA\") approval of a new drug application (\"NDA\") for lefamulin.  Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval.  If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full."}],"balance_after":22500,"derivative":{"expiration_date":"2021-01-31","underlying":"Ordinary Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001104659-18-006234","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465918006234/a4.xml","form_type":"4"}},{"id":4078433,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2018-02-02T16:11:51.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $6.47 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022.  Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":100000,"derivative":{"expiration_date":"2028-01-31","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-18-006234","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465918006234/a4.xml","form_type":"4"}},{"id":4201394,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2017-09-26T17:01:47.000Z","date":"2017-09-22","kind":"purchase","acquired":true,"shares":2000,"price":8.21,"value":16420.0,"ownership":{"direct":true},"balance_after":4200,"source":{"system":"sec-edgar","filing":"0001104659-17-058897","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465917058897/a4.xml","form_type":"4"}},{"id":4270890,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2017-06-28T10:01:08.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":113000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is 7.963 Euro."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":113000,"derivative":{"expiration_date":"2027-02-06","underlying":"Ordinary Shares","underlying_shares":113000},"source":{"system":"sec-edgar","filing":"0001104659-17-041909","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000110465917041909/a4.xml","form_type":"4"}},{"id":4270889,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2017-06-28T10:01:08.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":88800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is 6.50 Euro."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":88800,"derivative":{"expiration_date":"2026-05-30","underlying":"Ordinary Shares","underlying_shares":88800},"source":{"system":"sec-edgar","filing":"0001104659-17-041909","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000110465917041909/a4.xml","form_type":"4"}},{"id":4270888,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2017-06-28T10:01:08.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."}],"balance_after":2200,"source":{"system":"sec-edgar","filing":"0001104659-17-041909","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1659085/000110465917041909/a4.xml","form_type":"4"}},{"id":4459108,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":27192,"kind":"person","name":"Sender Gary","position":1,"cik":"0001659085","reported_name":"Sender Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2017-02-09T16:35:52.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":11300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is 79.63 Euro."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 7, 2017.  Vesting will begin on February 28, 2017 and end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":11300,"derivative":{"expiration_date":"2027-02-06","underlying":"Common Shares","underlying_shares":11300},"source":{"system":"sec-edgar","filing":"0001104659-17-007831","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465917007831/a4.xml","form_type":"4"}}]}